journal
https://read.qxmd.com/read/38490233/correction-to-lancet-haematol-2024-11-e216-27
#1
(no author information available yet)
No abstract text is available yet for this article.
March 12, 2024: Lancet Haematology
https://read.qxmd.com/read/38461850/sex-and-gender-reporting-advances-in-medicine
#2
EDITORIAL
The Lancet Haematology
No abstract text is available yet for this article.
March 7, 2024: Lancet Haematology
https://read.qxmd.com/read/38452789/fully-oral-regimen-with-decitabine-and-cedazuridine-plus-venetoclax-a-new-step-forward-for-older-or-unfit-patients-with-acute-myeloid-leukaemia
#3
JOURNAL ARTICLE
Anna Candoni
No abstract text is available yet for this article.
March 4, 2024: Lancet Haematology
https://read.qxmd.com/read/38452788/oral-decitabine-and-cedazuridine-plus-venetoclax-for-older-or-unfit-patients-with-acute-myeloid-leukaemia-a-phase-2-study
#4
JOURNAL ARTICLE
Alexandre Bazinet, Guillermo Garcia-Manero, Nicholas Short, Yesid Alvarado, Alex Bataller, Tareq Abuasab, Rabiul Islam, Kathryn Montalbano, Ghayas Issa, Abhishek Maiti, Musa Yilmaz, Nitin Jain, Lucia Masarova, Steven Kornblau, Elias Jabbour, Guillermo Montalban-Bravo, Caitlin R Rausch, Sherry Pierce, Courtney D DiNardo, Tapan Kadia, Naval Daver, Marina Konopleva, Xuelin Huang, Hagop Kantarjian, Farhad Ravandi
BACKGROUND: Hypomethylating agents combined with venetoclax are effective regimens in patients with acute myeloid leukaemia who are ineligible for intensive chemotherapy. Decitabine and cedazuridine (ASTX727) is an oral formulation of decitabine that achieves equivalent area-under-curve exposure to intravenous decitabine. We performed a single centre phase 2 study to evaluate the efficacy and safety of ASTX727 plus venetoclax. METHODS: This study enrolled patients with newly diagnosed (frontline treatment group) acute myeloid leukaemia who were ineligible for intensive chemotherapy (aged ≥75 years, an Eastern Cooperative Oncology Group [ECOG] performance status of 2-3, or major comorbidities) or relapsed or refractory acute myeloid leukaemia...
March 4, 2024: Lancet Haematology
https://read.qxmd.com/read/38437858/breaking-ground-in-haemophilia-b-gene-therapy-insights-from-the-hope-b-trial-and-beyond
#5
JOURNAL ARTICLE
Margareth C Ozelo
No abstract text is available yet for this article.
March 1, 2024: Lancet Haematology
https://read.qxmd.com/read/38437857/etranacogene-dezaparvovec-gene-therapy-for-haemophilia-b-hope-b-24-month-post-hoc-efficacy-and-safety-data-from-a-single-arm-multicentre-phase-3-trial
#6
JOURNAL ARTICLE
Michiel Coppens, Steven W Pipe, Wolfgang Miesbach, Jan Astermark, Michael Recht, Paul van der Valk, Bruce Ewenstein, Karen Pinachyan, Nicholas Galante, Sandra Le Quellec, Paul E Monahan, Frank W G Leebeek
BACKGROUND: Etranacogene dezaparvovec, the first gene therapy approved for haemophilia B treatment, was shown to be superior to treatment with continuous prophylactic factor IX in terms of bleeding protection 18 months after gene therapy in a phase 3 trial. We report post-hoc 24-month efficacy and safety data from this trial to evaluate the longer-term effects of etranacogene dezaparvovec in individuals with haemophilia B. METHODS: The phase 3 HOPE-B trial enrolled males aged 18 years or older with inherited haemophilia B, classified as severe (plasma factor IX activity level <1%) or moderately severe (plasma factor IX activity level ≥1% and ≤2%), with a severe bleeding phenotype and who were on stable continuous factor IX prophylaxis...
March 1, 2024: Lancet Haematology
https://read.qxmd.com/read/38432242/haemoglobin-thresholds-to-define-anaemia-from-age-6-months-to-65-years-estimates-from-international-data-sources
#7
JOURNAL ARTICLE
Sabine Braat, Katherine L Fielding, Jiru Han, Victoria E Jackson, Sophie Zaloumis, Jessica Xu Hui Xu, Gemma Moir-Meyer, Sophia M Blaauwendraad, Vincent W V Jaddoe, Romy Gaillard, Patricia C Parkin, Cornelia M Borkhoff, Charles D G Keown-Stoneman, Catherine S Birken, Jonathon L Maguire, Melanie Bahlo, Eliza M Davidson, Sant-Rayn Pasricha
BACKGROUND: Detection of anaemia is crucial for clinical medicine and public health. Current WHO anaemia definitions are based on statistical thresholds (fifth centiles) set more than 50 years ago. We sought to establish evidence for the statistical haemoglobin thresholds for anaemia that can be applied globally and inform WHO and clinical guidelines. METHODS: In this analysis we identified international data sources from populations in the USA, England, Australia, China, the Netherlands, Canada, Ecuador, and Bangladesh with sufficient clinical and laboratory information collected between 1998 and 2020 to obtain a healthy reference sample...
February 29, 2024: Lancet Haematology
https://read.qxmd.com/read/38432241/models-of-care-for-sickle-cell-disease-in-low-income-and-lower-middle-income-countries-a-scoping-review
#8
REVIEW
Laura Drown, Miriam Osei, Ada Thapa, Chantelle Boudreaux, Natasha Archer, Gene Bukhman, Alma J Adler
Sickle cell disease has a growing global burden falling primarily on low-income countries (LICs) and lower-middle-income countries (LMICs) where comprehensive care is often insufficient, particularly in rural areas. Integrated care models might be beneficial for improving access to care in areas with human resource and infrastructure constraints. As part of the Centre for Integration Science's ongoing efforts to define, systematise, and implement integrated care delivery models for non-communicable diseases (NCDs), this Review explores models of care for sickle cell disease in LICs and LMICs...
February 29, 2024: Lancet Haematology
https://read.qxmd.com/read/38432240/defining-global-thresholds-for-anaemia-a-challenging-mission
#9
JOURNAL ARTICLE
Jahnavi Daru, Javier Zamora
No abstract text is available yet for this article.
February 29, 2024: Lancet Haematology
https://read.qxmd.com/read/38373427/correction-to-lancet-haematol-2024-11-e114-26
#10
(no author information available yet)
No abstract text is available yet for this article.
February 16, 2024: Lancet Haematology
https://read.qxmd.com/read/38340740/correction-to-lancet-haematol-2024-11-e101-13
#11
(no author information available yet)
No abstract text is available yet for this article.
February 7, 2024: Lancet Haematology
https://read.qxmd.com/read/38330978/correction-to-lancet-haematol-2024-11-e38-50
#12
(no author information available yet)
No abstract text is available yet for this article.
February 5, 2024: Lancet Haematology
https://read.qxmd.com/read/38330977/diagnosis-and-management-of-pyruvate-kinase-deficiency-international-expert-guidelines
#13
REVIEW
Hanny Al-Samkari, Nadine Shehata, Kelly Lang-Robertson, Paola Bianchi, Andreas Glenthøj, Sujit Sheth, Ellis J Neufeld, David C Rees, Satheesh Chonat, Kevin H M Kuo, Jennifer A Rothman, Wilma Barcellini, Eduard J van Beers, Dagmar Pospíšilová, Ami J Shah, Richard van Wijk, Bertil Glader, Maria Del Mar Mañú Pereira, Oliver Andres, Theodosia A Kalfa, Stefan W Eber, Patrick G Gallagher, Janet L Kwiatkowski, Frédéric Galacteros, Carl Lander, Alejandra Watson, Riyad Elbard, Dore Peereboom, Rachael F Grace
Pyruvate kinase (PK) deficiency is the most common cause of chronic congenital non-spherocytic haemolytic anaemia worldwide, with an estimated prevalence of one in 100 000 to one in 300 000 people. PK deficiency results in chronic haemolytic anaemia, with wide ranging and serious consequences affecting health, quality of life, and mortality. The goal of the International Guidelines for the Diagnosis and Management of Pyruvate Kinase Deficiency was to develop evidence-based guidelines for the clinical care of patients with PK deficiency...
February 5, 2024: Lancet Haematology
https://read.qxmd.com/read/38316134/decitabine-plus-cedazuridine-and-venetoclax-the-promise-of-an-all-oral-therapy-for-patients-with-myelodysplastic-syndromes-and-chronic-myelomonocytic-leukaemia
#14
JOURNAL ARTICLE
https://read.qxmd.com/read/38316133/oral-decitabine-plus-cedazuridine-and-venetoclax-in-patients-with-higher-risk-myelodysplastic-syndromes-or-chronic-myelomonocytic-leukaemia-a-single-centre-phase-1-2-study
#15
JOURNAL ARTICLE
Alex Bataller, Guillermo Montalban-Bravo, Alexandre Bazinet, Yesid Alvarado, Kelly Chien, Sangeetha Venugopal, Jo Ishizawa, Danielle Hammond, Mahesh Swaminathan, Koji Sasaki, Ghayas C Issa, Nicholas J Short, Lucia Masarova, Naval G Daver, Tapan M Kadia, Simona Colla, Wei Qiao, Xuelin Huang, Rashmi Kanagal-Shamanna, Stephany Hendrickson, Farhad Ravandi, Elias Jabbour, Hagop Kantarjian, Guillermo Garcia-Manero
BACKGROUND: Hypomethylating agents are approved in higher-riskmyelodysplastic syndromes. The combination of a hypomethylating agent with venetoclax is standard of care in acute myeloid leukaemia. We investigated the safety and activity of the first totally oral combination of decitabine plus cedazuridine and venetoclax in patients with higher-risk-myelodysplastic syndromes and chronic myelomonocytic leukaemia. METHODS: We did a single-centre, dose-escalation and dose-expansion, phase 1/2, clinical trial...
February 2, 2024: Lancet Haematology
https://read.qxmd.com/read/38301671/extending-potentially-curative-options-for-older-patients-with-pcnsl
#16
JOURNAL ARTICLE
Elizabeth H Phillips, Kate Cwynarski
No abstract text is available yet for this article.
January 29, 2024: Lancet Haematology
https://read.qxmd.com/read/38301670/high-dose-chemotherapy-and-autologous-haematopoietic-stem-cell-transplantation-in-older-fit-patients-with-primary-diffuse-large-b-cell-cns-lymphoma-marta-a-single-arm-phase-2-trial
#17
JOURNAL ARTICLE
Elisabeth Schorb, Lisa Kristina Isbell, Andrea Kerkhoff, Stephan Mathas, Friederike Braulke, Gerlinde Egerer, Alexander Röth, Simon Schliffke, Peter Borchmann, Uta Brunnberg, Frank Kroschinsky, Robert Möhle, Andreas Rank, Dominique Wellnitz, Benjamin Kasenda, Lisa Pospiech, Julia Wendler, Florian Scherer, Martina Deckert, Elina Henkes, Philipp von Gottberg, Dennis Gmehlin, Matthias Backenstraß, Antje Jensch, Elvira Burger-Martin, Olga Grishina, Heidi Fricker, Natalie Malenica, András Orbán, Justus Duyster, Gabriele Ihorst, Juergen Finke, Gerald Illerhaus
BACKGROUND: Available treatments for older patients with primary diffuse large B-cell CNS lymphoma (PCNSL) offer progression-free survival of up to 16 months. We aimed to investigate an intensified treatment of high-dose chemotherapy and autologous haematopoietic stem-cell transplantation (HSCT) in older patients with PCNSL. METHODS: MARTA was a prospective, single-arm, phase 2 study done at 15 research hospitals in Germany. Patients aged 65 years or older with newly diagnosed, untreated PCNSL were enrolled if they had an Eastern Cooperative Oncology Group performance status of 0-2 and were fit for high-dose chemotherapy and autologous HSCT...
January 29, 2024: Lancet Haematology
https://read.qxmd.com/read/38142694/extended-duration-of-letermovir-prophylaxis-how-long-is-long-enough
#18
JOURNAL ARTICLE
Abby P Douglas, Monica A Slavin
No abstract text is available yet for this article.
December 21, 2023: Lancet Haematology
https://read.qxmd.com/read/38428445/health-care-transition-services-for-sickle-cell-disease-in-brazil
#19
JOURNAL ARTICLE
Jane S Hankins, Clarisse Lobo, Josefina A P Braga, Tarun Aurora, Kelly Pimenta, Maria Stella Figueiredo, Ana A Baumann
No abstract text is available yet for this article.
March 2024: Lancet Haematology
https://read.qxmd.com/read/38428444/gender-composition-and-geographical-representation-of-american-society-of-hematology-clinical-practice-guideline-authors
#20
JOURNAL ARTICLE
Jeremy W Jacobs, Amarilis A Martin, Laura D Stephens, Brian D Adkins, Jennifer S Woo, Deva Sharma, Allison P Wheeler, Raeshun T Glover, Jennifer C Yui, Shannon C Walker, Shazia S Khan, Garrett S Booth, Julie K Silver
No abstract text is available yet for this article.
March 2024: Lancet Haematology
journal
journal
49595
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.